International consensus on allergy immunotherapy - 04/09/15
Doi : 10.1016/j.jaci.2015.04.047
Marek Jutel, MD a, ⁎ 
, Ioana Agache, MD b, Sergio Bonini, MD c, A. Wesley Burks, MD d, Moises Calderon, MD e, Walter Canonica, MD f, Linda Cox, MD g, Pascal Demoly, MD h, Antony J. Frew, MD i, Robin O'Hehir, MD j, Jörg Kleine-Tebbe, MD k, Antonella Muraro, MD l, Gideon Lack, MD m, Désirée Larenas, MD n, Michael Levin, MD o, Harald Nelson, MD p, Ruby Pawankar, MD q, Oliver Pfaar, MD r, Ronald van Ree, PhD s, Hugh Sampson, MD t, Alexandra F. Santos, MD, PhD u, George Du Toit, MD u, Thomas Werfel, MD v, Roy Gerth van Wijk, MD w, Luo Zhang, MD x, Cezmi A. Akdis, MD y
, Ioana Agache, MD b, Sergio Bonini, MD c, A. Wesley Burks, MD d, Moises Calderon, MD e, Walter Canonica, MD f, Linda Cox, MD g, Pascal Demoly, MD h, Antony J. Frew, MD i, Robin O'Hehir, MD j, Jörg Kleine-Tebbe, MD k, Antonella Muraro, MD l, Gideon Lack, MD m, Désirée Larenas, MD n, Michael Levin, MD o, Harald Nelson, MD p, Ruby Pawankar, MD q, Oliver Pfaar, MD r, Ronald van Ree, PhD s, Hugh Sampson, MD t, Alexandra F. Santos, MD, PhD u, George Du Toit, MD u, Thomas Werfel, MD v, Roy Gerth van Wijk, MD w, Luo Zhang, MD x, Cezmi A. Akdis, MD y a Department of Clinical Immunology, Wrocław Medical University, and “ALL-MED” Medical Research Institute, Wrocław, Poland
b Faculty of Medicine, Transylvania University, Brasov, Romania
c Second University of Naples and IFT-CNR, Rome, and Expert-on-Secondment European Medicines Agency, London, United Kingdom
d Department of Pediatrics, University of North Carolina, Chapel Hill, NC
e Section of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Royal Brompton Hospital, London, United Kingdom
f Allergy & Respiratory Diseases Clinic, DIMI–University of Genoa, IRCCS AOU S. Martino, Genoa, Italy
g Allergy and Asthma Center, Ft Lauderdale, Fla
h University Hospital of Montpellier–INSERM U657, Montpellier, France
i Department of Respiratory Medicine, Royal Sussex County Hospital, Brighton, United Kingdom
j Department of Immunology, AMREP, Monash University, Melbourne, Australia
k Allergy & Asthma Center Westend, Berlin, Germany
l Department of Mother and Child Health, Padua General University Hospital, Padua, Italy
m Division of Asthma, Allergy and Lung Biology, MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, and the Children's Allergy Unit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
n Hospital Médica Sur, Mexico City, Mexico
o Division of Allergy, School of Child and Adolescent Health, Red Cross War Memorial Children's Hospital, Cape Town, South Africa
p National Jewish Health, Denver, Colo
q Department of Pediatrics, Nippon Medical School, Tokyo, Japan
r Center for Rhinology and Allergology, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany
s Academic Medical Center, Departments of Experimental Immunology and of Otorhinolaryngology, University of Amsterdam, Amsterdam, The Netherlands
t Department of Pediatrics, Division of Allergy-Immunology, and the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, New York, NY
u Department of Pediatric Allergy, Division of Asthma, Allergy & Lung Biology, King's College London, and MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
v Department of Dermatology and Allergy, Division of Immunodermatology and Allergy Research, Hannover Medical School, Hannover, Germany
w Erasmus Medical Center, Rotterdam, The Netherlands
x Beijing Institute of Otolaryngology, Beijing, China
y Swiss Institute for Allergy and Asthma Research, University of Zurich, Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland
∗Corresponding author: Marek Jutel, MD, Wrocław Medical University, Department of Clinical Immunology, Chalubinskiego 5, PL-50-368 Wrocław, Poland.
Abstract |
Allergen immunotherapy (AIT) has been used to treat allergic disease since the early 1900s. Despite numerous clinical trials and meta-analyses proving AIT efficacious, it remains underused and is estimated to be used in less than 10% of patients with allergic rhinitis or asthma worldwide. In addition, there are large differences between regions, which are not only due to socioeconomic status. There is practically no controversy about the use of AIT in the treatment of allergic rhinitis and allergic asthma, but for atopic dermatitis or food allergy, the indications for AIT are not well defined. The elaboration of a wider consensus is of utmost importance because AIT is the only treatment that can change the course of allergic disease by preventing the development of asthma and new allergen sensitizations and by inducing allergen-specific immune tolerance. Safer and more effective AIT strategies are being continuously developed both through elaboration of new allergen preparations and adjuvants and alternate routes of administration. A number of guidelines, consensus documents, or both are available on both the international and national levels. The international community of allergy specialists recognizes the need to develop a comprehensive consensus report to harmonize, disseminate, and implement the best AIT practice. Consequently, the International Collaboration in Asthma, Allergy and Immunology, formed by the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the World Allergy Organization, has decided to issue an international consensus on AIT.
Le texte complet de cet article est disponible en PDF.Key words : International consensus, allergy, immunotherapy, allergen vaccine, allergic rhinitis, asthma, food allergy, atopic dermatitis
Abbreviations used : AD, AIT, AR, EAACI, HDM, LR, OIT, SCIT, SLIT, SR, WAO
Plan
| Disclosure of potential conflict of interest: M. Jutel has received research support from the Polish National Science Centre and lecture fees from Allergopharma and Stallergenes. S. Bonini has provided expert testimony for the European Medicines Agency. A. W. Burks is on the FARE and World Allergy Organization boards; is on the Murdoch Children's Research Institute advisory board; has received consultancy fees from Gerson Lehrman Group, ActoGeniX, Genentech, Sanofi US, Valeant Pharmaceuticals North America; has provided unpaid consultation for Dynavax Technologies, Perrigo Company (PBN Nutritionals), and Perosphere; is employed by the University of North Carolina; has patents (US5558869, US55973121, US6441142, US6486311, US6835824, US7485708, and US7879977); has received payment for developing educational presentations from Current Views 2012; and has stock/stock options in Allertein and Mastcell Pharmaceuticals. M. Calderon has received consultancy fees from ALK-Abelló, STG, and Hal Allergy; has received lecture fees from ALK-Abelló STG, and Allergopharma; and has received travel support from ALK-Abelló, STG, Allergopharma, and Hal Allergy. W. Canonica has received consulting fees from ALK-Abelló, Allergy Therapeutics, Lofarma, and Stallergenes. L. Cox has received consulting fees from Greer, has received fees for participation in review activities from Circassia and Biomay, is on the American Board of Allergy and Immunology and American Academy of Allergy, Asthma & Immunology Boards, and has received lecture fees from Southeastern Allergy Asthma Immunology Association. P. Demoly has received consultancy fees from ALK-Abelló, Circassia, Stallergenes, Allergopharma, Thermo Fisher Scientific, DBV, Chiesi, and Pierre Febre Medicaments and has received lecture fees from Menarini, MSD, AstraZeneca, and GlaxoSmithKline. J. Kleine-Tebbe is on the ALK-Abelló, Novartis, Leti, and Bencard advisory boards; has received consultancy fees from Merck and Circassia; has received research support from Circassia; and has received lecture fees from Allergopharma, ALK-Abelló, Bencard, HAL Allergy, LETI, Lofarma, Novartis, and Stallergenes. A. Muraro has received consultancy fees from Meda, Nutricia, Allergopharma, and Novartis. G. Lack has stock/stock options in DBV Technologies. D. Larenas is on the CMICA board; has received consultancy fees from Meda, Pfizer, MIT, Boehringer Ingelheim, Novartis, and Glenmark; has received research support from Novartis, Pfizer, Meda, UCB, GlaxoSmithKline, AstraZeneca, Sunovion, Sanofi, MSD, Teva, and Commet; has received lecture fees from AstraZeneca, Glenmark, MSD, UCB, Meda, and Pfizer; has received payment for developing educational presentations from Glenmark; and has received travel support from MSD, UCB, AstraZeneca, Pfizer, Meda, Senosiain, Glenmark, ALK-Abelló, Novartis, and Chiesi. H. Nelson is on the advisory board for Merck and Circassia, is on the data monitoring board for AstraZeneca and Pearl Therapeutics, and has received research support from Circassia. O. Pfaar has received consultancy fees from Bencard (Germany), HAL-Allergy (The Netherlands), Novartis/LETI (Germany), MEDA (Germany), ALK-Abelló (Germany/Denmark), Allergopharma (Germany), Biotech Tools s.a. (Belgium), GfK Bridgehead (United Kingdom), NAVIGANT-consulting (United States), Sanofi (United States), Guidepoint Global Advisors (United States), Stallergenes (Germany/France), and Mobile Chamber Experts (MCX), a GA2LEN Partner (Germany); is employed by Universitätsmedizin Mannheim, Heidelberg University; has received research support from ALK-Abelló (Germany/Denmark), Allergopharma (Germany), Stallergenes (Germany/France), HAL-Allergy (Germany/The Netherlands), Artu Biologicals (The Netherlands), Allergy Therapeutics/Bencard (UK/Germany), Hartington (Spain), Lofarma (Italy), Novartis/Leti (Germany/Spain), GlaxoSmithKline (United Kingdom/Germany), Essex-Pharma (Germany), Cytos (Switzerland), Curalogic (Denmark), Roxall (Germany), Biomay (Austria), Thermo Fisher (Germany), Circassia (UK), E.U (FP-7-Health-2013-Innovation 1), Biotech Tools s.a. (Belgium), and MEDA-Pharma GmbH (Germany); has received lecture fees from ALK-Abelló (Germany/Denmark), Allergopharma (Germany), Stallergenes (Germany/France), HAL-Allergy (Germany/The Netherlands), Allergy Therapeutics/Bencard (United Kingdom/Germany), Hartington (Spain), Lofarma (Italy), Novartis/Leti (Germany/Spain), GlaxoSmithKline (United Kingdom/Germany), Roxall (Germany), Thermo Fisher (Germany), and MEDA-Pharma GmbH (Germany); is coeditor and author of textbook “Allergien bei Kindern und Jugendlichen” (Schattauer, Germany), author of different chapters of “Allergologie-Handbuch” (Schattauer, Germany), and author of 1 chapter in “Allergologie” (Springer, Germany); has received payment for developing educational presentations from GlaxoSmithKline (Germany), Bencard (Germany), and Novartis (Germany); has received travel support from HAL-Allergy (Netherlands/Germany) and Allergopharma (Germany); and is current chairman of IT IG of European Academy of Allergy and Clinical Immunology (EAACI), and current secretary of ENT-section of DGAKI. R. van Ree is on the EAACI board, has received consultancy fees from HAL Allergy BV, has received research support from the European Union, and has received lecture fees from Thermo Fisher Scientific. H. Sampson is an unpaid consultant on the DBV Scientific Advisory Board. G. Du Toit has received lecture fees from Thermo Fisher, owns 2% equity of the FoodMaestro app, and has received travel support from the EAACI as secretary of the paediatric section. R. Gerth van Wijk has received consultancy fees from MSD, HAL, Crucell, ALK-Abelló, and Novartis; has received research support from NWO, STW, Novartis, Biomay, and DBV; has received lecture fees from Allergopharma and Thermo Fisher; has received payment for manuscript preparation from Chiesi; and receives royalties from de Tijdstroom and Bohn, Stafleu, van Loghum. C. A. Akdis has received consultancy fees from Actellion, Aventis, Stallergenes, Allergopharma, and Circacia; is employed by the Swiss Institute of Allergy and Asthma Research, University of Zuurich; has received research support from Novartis, PREDICTA, Swiss National Science Foundation, MeDALL (Programme no. 261357), and the Christine-Kuhne Center for Allergy Research and Education. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2015
Publié par Elsevier Masson SAS.
Vol 136 - N° 3
P. 556-568 - septembre 2015 Retour au numéro
Article précédent
- Understanding the pathophysiology of the asthma–chronic obstructive pulmonary disease overlap syndrome
- Arthur F. Gelb, Jay A. Nadel
- The Editors' Choice
- Donald Y.M. Leung, Stanley J. Szefler, Associate Editors of the JACI
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?